As insulin resistance promotes dysregulation of peripheral lipolysis and de novo lipogenesis, which then leads to accumulation of free fatty acids in the liver [2], the effects of GLP-1 agonists on hepatic steatosis might be less prominent when hyperinsulinemia and hyperglycemia are not present and seem not to be directly correlated with their anti-inflammatory properties. The gene discussed is GCG; the disease is Insulin resistance.